✦ LIBER ✦

Phase II trial of irinotecan plus cisplatin in patients with recurrent or metastatic squamous carcinoma of the head and neck

✍ Scribed by Jill Gilbert; Anthony Cmelak; Yu Shyr; James Netterville; Brian B. Burkey; Robert J. Sinard; Wendall G. Yarbrough; Christine H. Chung; Joseph M. Aulino; Barbara A. Murphy

Publisher: John Wiley and Sons
Year: 2008
Tongue: English
Weight: 86 KB
Volume: 113
Category: Article
ISSN: 0008-543X
DOI: 10.1002/cncr.23545

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

A phase II trial of cisplatin and vinore

A phase II trial of cisplatin and vinorelbine in patients with recurrent or metastatic squamous cell carcinoma of the head and neck

✍ Enrique Espinosa; Pilar Zamora; Alfredo Millá; Serafin Morales; Raquel Molina; M 📂 Article 📅 2002 🏛 John Wiley and Sons 🌐 English ⚖ 75 KB 👁 1 views

## Abstract ## Objective. We assessed the response rate and the toxicity of cisplatin plus vinorelbine in patients with this condition. ## Patients and Method. Forty‐two patients were included. Therapy consisted of cisplatin, 100 mg/m^2^ on day 1, and vinorelbine, 25 mg/m^2^ on days 1 and 8, giv

Phase II study of paclitaxel, ifosfamide

Phase II study of paclitaxel, ifosfamide, and carboplatin in patients with recurrent or metastatic head and neck squamous cell carcinoma

✍ Dong M. Shin; Fadlo R. Khuri; Bonnie S. Glisson; Lawrence Ginsberg; Vali M. Papa 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB 👁 2 views

Vinblastine, bleomycin and cisplatin for

Vinblastine, bleomycin and cisplatin for recurrent or metastatic squamous cell carcinoma of the head and neck

✍ David J. Perry; Martin D. Weltz; Archie W. Brown Jr; Robert L. Henderson; Willia 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 315 KB 👁 2 views

Forty-two patients with recurrent or metastatic squamous cell carcinoma of the head and neck were treated with vinblastine, bleomycin, and cisplatin. All patients had received prior surgery, radiation or chemotherapy and all had measurable disease. Forty-five percent of the patients responded with a

Weekly docetaxel in patients with recurr

Weekly docetaxel in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck

✍ Ricardo Hitt; Maria L. Amador; Miguel Quintela-Fandino; Antonio Jimeno; Olga del 📂 Article 📅 2006 🏛 John Wiley and Sons 🌐 English ⚖ 107 KB 👁 2 views

Phase II study of the antiangiogenesis a

Phase II study of the antiangiogenesis agent thalidomide in recurrent or metastatic squamous cell carcinoma of the head and neck

✍ Jennifer E. Tseng; Bonnie S. Glisson; Fadlo R. Khuri; Dong M. Shin; Jeffrey N. M 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 241 KB 👁 2 views

Paclitaxel, cisplatin, and 5-fluorouraci

Paclitaxel, cisplatin, and 5-fluorouracil for patients with advanced or recurrent squamous cell carcinoma of the head and neck

✍ Maha Hussain; Shirish Gadgeel; Omer Kucuk; Wei Du; Walter Salwen; John Ensley 📂 Article 📅 1999 🏛 John Wiley and Sons 🌐 English ⚖ 73 KB 👁 3 views

## BACKGROUND. The combination of cisplatin and 5-flurouracil (5-FU) is considered standard therapy for patients with recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN). Paclitaxel has exhibited single-agent activity in patients with this disease. The authors conducted thi